---
title: "Update: Regenxbio Shares Fall After Q1 Swings to Loss, Revenue Declines; Phase 3 Study of RGX-202 Meets Primary Endpoint"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/286455339.md"
description: "Regenxbio's shares fell 36% after reporting a Q1 net loss of $1.72 per diluted share, down from earnings of $0.12 a year earlier. Revenue dropped to $6.4 million from $89.0 million, missing analyst expectations. The company has $150.5 million in cash to fund operations into early 2027. However, its gene therapy RGX-202 met primary endpoints in a Phase 3 trial, with plans for accelerated approval and a potential commercial launch in 2027."
datetime: "2026-05-14T18:39:00.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/286455339.md)
  - [en](https://longbridge.com/en/news/286455339.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/286455339.md)
---

# Update: Regenxbio Shares Fall After Q1 Swings to Loss, Revenue Declines; Phase 3 Study of RGX-202 Meets Primary Endpoint

02:39 PM EDT, 05/14/2026 (MT Newswires) -- (Updates with latest stock price movement in the headline and first paragraph, Q1 earnings in the second through sixth paragraphs.)

Regenxbio's ( RGNX ) shares were down about 36% in Thursday afternoon trading after its Q1 swung to a loss and revenue declined.

The company reported a Q1 net loss Thursday of $1.72 per diluted share, swinging from earnings of $0.12 a year earlier.

Analysts polled by FactSet expected a loss of $1.34.

Revenue for the quarter ended March 31 fell to $6.4 million from $89.0 million a year earlier.

Analysts surveyed by FactSet expected $25.8 million.

The company expects its cash, cash equivalents and marketable securities of $150.5 million as of March 31 to fund its operations into early 2027.

Separately, the company said Thursday its investigational gene therapy RGX-202 met the primary endpoint in the pivotal phase III portion of the Affinity Duchenne trial for Duchenne Muscular Dystrophy.

The company said 93% of patients achieved over 10% microdystrophin expression at week 12.

Regenxbio ( RGNX ) said it is preparing to pursue accelerated approval based on the data and is targeting a potential commercial launch in 2027.

Price: 6.47, Change: -3.57, Percent Change: -35.56

MT Newswires does not provide investment advice. Unauthorized reproduction is strictly prohibited.

### Related Stocks

- [RGNX.US](https://longbridge.com/en/quote/RGNX.US.md)
- [IBB.US](https://longbridge.com/en/quote/IBB.US.md)
- [BIB.US](https://longbridge.com/en/quote/BIB.US.md)
- [FBT.US](https://longbridge.com/en/quote/FBT.US.md)
- [PBE.US](https://longbridge.com/en/quote/PBE.US.md)
- [LABU.US](https://longbridge.com/en/quote/LABU.US.md)
- [SBIO.US](https://longbridge.com/en/quote/SBIO.US.md)
- [BBH.US](https://longbridge.com/en/quote/BBH.US.md)
- [IBBQ.US](https://longbridge.com/en/quote/IBBQ.US.md)
- [XBI.US](https://longbridge.com/en/quote/XBI.US.md)
- [FDS.US](https://longbridge.com/en/quote/FDS.US.md)

## Related News & Research

- [REGENXBIO Announces Positive Topline Results from Pivotal Phase III AFFINITY DUCHENNE® Study of RGX-202 | RGNX Stock News](https://longbridge.com/en/news/286403513.md)
- [REGENXBIO Advances Duchenne Gene Therapy Toward Accelerated Approval](https://longbridge.com/en/news/286443456.md)
- [RegenXBio Advances RGX-202 With Positive Phase III Results](https://longbridge.com/en/news/286412399.md)
- [REGENXBIO Reports First Quarter 2026 Financial Results and Operational Highlights | RGNX Stock News](https://longbridge.com/en/news/286405286.md)
- [16:05 ETREGENXBIO to Participate in Upcoming Investor Conferences](https://longbridge.com/en/news/286813324.md)